Monograph Details
|
|
Ob/Gyn
> Contraception
|
|
ORTHO EVRA |
| Manufacturer |
|
Ortho-McNeil Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Progestin + estrogen. |
| Generic Name |
|
Norelgestromin 150micrograms/day, ethinyl estradiol 20micrograms/day; transdermal patch. |
| Indications |
|
Transdermal contraception. |
| Children |
|
Premenarchal: not applicable. |
| Adults |
|
Apply to abdomen, buttock, upper outer arm, or upper torso (excluding breasts); with each new patch, rotate application site (may use same anatomic area). Apply 1 patch once weekly for 3 weeks, then 1 patch-free week; repeat. |
| Contraindications |
|
See literature. Thrombophlebitis or thromboembolic disorders. Breast or other estrogen-dependent neoplasms. Hepatic adenoma or carcinoma. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use. Pregnancy (Cat.X). |
| Precautions |
|
See literature. May be less effective in patients ≥90 kg (198 lbs). Smokers (>15 cigarettes/day) >35 years of age: not recommended. Higher estrogen exposure than oral contraceptives (may increase side effect risk). Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Uncontrolled hypertension. Do regular complete physical exams. Use barrier contraception with Sunday starts or postpartum starts (see literature). Nursing mothers: not recommended. |
| Interactions |
|
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's Wort), possibly others. |
| Adverse Reactions |
|
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, application site reactions, possible venous thromboembolism; others (see literature). |
| How Supplied |
|
Patches—1, 3 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
